This company is now a one-trick pony, with superior drugs like Nexavar showing greater efficacy over a much wider range of conditions.Most analysts are rating this one a strong sell.
ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024